ScreenerHero

NCNA NuCana plc

NAS · US · Healthcare · Biotechnology · nucana.com
1.140USD+4.59%Mkt Cap: 4.74M $P/E: —

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.74M USD
Enterprise Value-14.13M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.35M USD
Revenue/Share—
Last Price1.140 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.12
PEG—
EV/EBITDA0.98
EV/Revenue—
P/S—
P/B0.18
EPS (TTM)0.00
EPS (Forward)-9.43
52W Range
0.94843% of range7.220
52W High7.220 USD
52W Low0.9484 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-120.66%
ROA-98.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.47M USD
CapEx (TTM)193.00K USD
FCF Margin—
FCF Yield-134.26%
Net Debt-18.83M USD
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.03
Current Ratio4.73
Quick Ratio4.56
Book Value/Sh6.22 USD
Cash/Share4.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:200
Split DateAug 11, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.16M
Float4.31M
Insiders0.00%
Institutions2.60%
Short Interest
Short Ratio1.2d
Short % Float2.57%
Short % Out.2.57%
Shares Short107.13K
Short (prev mo.)134.39K
Technical
SMA 501.376 (-17.2%)
SMA 2001.983 (-42.5%)
Beta2.31
S&P 52W Chg15.78%
Avg Vol (30d)102.81K
Avg Vol (10d)463.85K
Technical Indicators
RSI (14)39.9
MACD-0.0802
MACD Signal-0.0615
MACD Hist.-0.0187
BB Upper1.472 USD
BB Middle1.268 USD
BB Lower1.063 USD
BB Width32.29%
ATR (14)0.1259 USD
Vol Ratio (20d)0.57x